- Home
- CMPS vs FINS Comparison
CMPS vs FINS Comparison
Compare CMPS & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- FINS
- Stock Information
- Founded
- CMPS 2020
- FINS 2019
- Country
- CMPS United Kingdom
- FINS United States
- Employees
- CMPS N/A
- FINS N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- FINS Finance/Investors Services
- Sector
- CMPS Health Care
- FINS Finance
- Exchange
- CMPS Nasdaq
- FINS Nasdaq
- Market Cap
- CMPS 487.4M
- FINS 447.8M
- IPO Year
- CMPS 2020
- FINS N/A
- Fundamental
- Price
- CMPS $6.34
- FINS $13.22
- Analyst Decision
- CMPS Strong Buy
- FINS
- Analyst Count
- CMPS 7
- FINS 0
- Target Price
- CMPS $17.00
- FINS N/A
- AVG Volume (30 Days)
- CMPS 1.5M
- FINS 78.0K
- Earning Date
- CMPS 10-30-2025
- FINS 01-01-0001
- Dividend Yield
- CMPS N/A
- FINS 9.97%
- EPS Growth
- CMPS N/A
- FINS N/A
- EPS
- CMPS N/A
- FINS N/A
- Revenue
- CMPS N/A
- FINS N/A
- Revenue This Year
- CMPS N/A
- FINS N/A
- Revenue Next Year
- CMPS N/A
- FINS N/A
- P/E Ratio
- CMPS N/A
- FINS N/A
- Revenue Growth
- CMPS N/A
- FINS N/A
- 52 Week Low
- CMPS $2.25
- FINS $11.61
- 52 Week High
- CMPS $6.63
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- CMPS 73.27
- FINS 55.05
- Support Level
- CMPS $5.54
- FINS $13.00
- Resistance Level
- CMPS $6.62
- FINS $13.26
- Average True Range (ATR)
- CMPS 0.33
- FINS 0.13
- MACD
- CMPS 0.08
- FINS 0.00
- Stochastic Oscillator
- CMPS 86.39
- FINS 73.13
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.